ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber Sells 84,103 Shares

ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber sold 84,103 shares of the company’s stock in a transaction on Friday, April 12th. The stock was sold at an average price of $1.73, for a total transaction of $145,498.19. Following the completion of the transaction, the senior vice president now owns 189,670 shares of the company’s stock, valued at $328,129.10. The sale was disclosed in a filing with the SEC, which is available at this link.

ProKidney Stock Performance

NASDAQ:PROK opened at $2.84 on Thursday. The firm has a market cap of $651.33 million, a P/E ratio of -4.98 and a beta of 1.08. ProKidney Corp. has a fifty-two week low of $1.12 and a fifty-two week high of $13.51. The firm has a 50-day simple moving average of $1.56 and a two-hundred day simple moving average of $1.80.

ProKidney (NASDAQ:PROK) last released its quarterly earnings data on Thursday, March 21st. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. On average, equities research analysts predict that ProKidney Corp. will post -0.65 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Morgan Stanley assumed coverage on shares of ProKidney in a report on Thursday, March 7th. They issued an “equal weight” rating and a $3.00 price objective for the company. Bank of America lowered shares of ProKidney from a “buy” rating to a “neutral” rating in a report on Tuesday, January 2nd.

Institutional Trading of ProKidney

Institutional investors have recently made changes to their positions in the stock. Lazard Asset Management LLC purchased a new stake in shares of ProKidney during the 2nd quarter valued at about $31,000. Tower Research Capital LLC TRC boosted its holdings in shares of ProKidney by 98.5% during the 1st quarter. Tower Research Capital LLC TRC now owns 4,456 shares of the company’s stock valued at $50,000 after acquiring an additional 2,211 shares during the last quarter. Ameritas Investment Partners Inc. purchased a new stake in shares of ProKidney during the 2nd quarter valued at about $57,000. UBS Group AG boosted its holdings in shares of ProKidney by 97.5% during the 1st quarter. UBS Group AG now owns 5,209 shares of the company’s stock valued at $59,000 after acquiring an additional 2,571 shares during the last quarter. Finally, Royal Bank of Canada boosted its holdings in shares of ProKidney by 530.3% during the 2nd quarter. Royal Bank of Canada now owns 6,965 shares of the company’s stock valued at $78,000 after acquiring an additional 5,860 shares during the last quarter. Hedge funds and other institutional investors own 51.59% of the company’s stock.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.